Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Reata Pharmaceuticals Inc (RETA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Reata Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Reata Pharma historical data, for real-time data please try another search
172.36 +0.00    +0.00%
25/09 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 172.32 - 172.46
Reata Pharma 172.36 +0.00 +0.00%

Reata Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Reata Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

322

Equity Type

ORD

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. As of September 26, 2023, Reata Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Contact Information

Address 5320 Legacy Drive
Plano, 75024
United States
Phone 972 865 2219
Fax -
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RETA Comments

Write your thoughts about Reata Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Mccray
William Mccray Mar 01, 2023 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Would have been nice if https://investing.com listed this earlier when the market opened as being over 200% higher
Wiwid Yuliardi
Wiwid Yuliardi Mar 01, 2023 11:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
go to 120
Waylin McCurley
Waylin McCurley Mar 01, 2023 9:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
congrats longs
Waylin McCurley
Waylin McCurley Mar 01, 2023 9:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wow, I sold.
Beni Nicksan
Beni Nicksan Feb 27, 2023 12:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I will go short on it
Fernando Rascón
Fernando Rascón Feb 27, 2023 12:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
are u ok
Beni Nicksan
Beni Nicksan Feb 27, 2023 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fall
Beni Nicksan
Beni Nicksan Feb 27, 2023 12:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🔻🔻🔻
Robi Zambo
Robi Zambo Feb 27, 2023 12:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
25 next small support
CARLOS ESCOBARVAZQUEZ
CARLOS ESCOBARVAZQUEZ Aug 16, 2022 11:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good
Mohamad Bustami
Mohamad Bustami Feb 28, 2022 11:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀🚀🚀
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email